44 results about "Methemoglobin" patented technology

Non-invasive, optical apparatus and methods for the direct measurement of hemoglobin derivatives and other analyte concentration levels in blood using diffuse reflection and transmission spectroscopy in the wavelength region 400-1350 nm which includes the transparent tissue window from approximately 610 to 1311 nanometers and, using diffuse reflection spectroscopy, the mid-infrared region from 4.3-12 microns in wavelength. Large area light collection techniques are utilized to provide a much larger pulsate signal than can be obtain with current sensor technology. Sensors used in separate or simultaneous precision measurements of both diffuse reflection and transmission, either separately or simultaneously, from pulsate, blood-perfused tissue for the subsequent determination of the blood analytes concentrations such as arterial blood oxygen saturation (SaO2), carboxyhemoglobin (COHb), oxyhemoglobin (OHb), deoxyhemoglobin (dOHb), methemoglobin (metHb), water (H2O), hematocrit (HCT), glucose, cholesterol and proteins such as albumin and other analytes components.

A high temperature-stable and highly purified cross-linked (optionally ≧70% β-β linked) tetrameric hemoglobin with high efficiency of oxygen delivery suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of hemoglobin is degenerated and purification processes are performed on red blood cells from whole blood. Controlled hypotonic lysis in an instant cytolysis apparatus prevents lysis of white blood cells. Nucleic acids from white blood cells and phospholipids impurities are not detected. Blocking of reactive sulfhydryl groups by a sulfhydryl reagent is performed in an oxygenated environment. Flowthrough column chromatography removes different plasma protein impurities. N-acetyl cysteine is added to the cross-linked tetrameric hemoglobin to maintain a low level of met-hemoglobin. The stabilized hemoglobin is preserved in an infusion bag with aluminum overwrap to prevent formation of inactive met-hemoglobin from oxygen intrusion. The product finds use in tissue oxygenation and cancer treatment.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

The present invention provides an agent containing L-tyrosine that prevents methemoglobin formation, and a vesicle comprising the above agent for preventing methemoglobin formation. More specifically, the present invention provides an oxygen infusion preparation suitable for long-term storage, which prevents an increase in methemoglobin content as a result of oxidation of hemoglobin or the like encapsulated in an vesicle having a lipid bilayer membrane structure.

A reagent for measurement of leukocytes and hemoglobin concentration in the blood includes a cationic surfactant in an amount sufficient to lyse erythrocytes and denature hemoglobin, at least one of the following hemoglobin stabilizers:(a) sulfosalicylic acid, or its salt, in an amount effective for promoting the conversion of hemoglobin into methemoglobin,(b) 0.2 to 10.0 g / L of a water-soluble chelating agent having a nitrogen atom and a carboxyl group, and(c) piperazine, or its salt, in an amount effective for promoting the conversion of hemoglobin into methemoglobin, anda buffer for maintaining pH at 4 to 6.

A method of treating a human subject which is effected by intermittent breathing cycle-coordinated pulse delivery inhalation of gaseous nitric oxide at a concentration of at least 160 ppm, or at a load per cycle of 80 ppm-hour, is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

A combined diluent and lysing reagent for simultaneously counting or analysis of various blood cells such as thrombocytes, leukocytes and leukocyte subpopulations, as well as analysis of hemoglobin. The reagent comprises a hemoglobin stabilizing / methemoglobin ligand compound selected from the group consisting of imidazole, imidazole derivatives, and combinations thereof, at least two quaternary ammonium salts, 1,3-dimethylurea and / or salts thereof; and an organic buffer. Accordingly, the reagent can be used in a method for determining the content of blood cells in a blood sample comprising: mixing a blood sample with a reagent according to the invention; and analyzing the content of the blood sample by employment of the Coulter principle and optionally an spectrophotometric analysis of the hemoglobin content.

A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngealcarcinoma and esophageal cancer.,The inventive tetrameric hemoglobin can also be used to prevent tumor metastasis and recurrence following surgical tumor excision. Further the inventive tetrameric hemoglobin can be administered to patients prior to chemotherapy and radiation treatment.

The invention discloses a deoxygenation method for a natural hemoglobin blood substitute. The deoxygenation method comprises the following steps: adding a small molecule antioxidant and a sugar protective agent into an isotonic system containing natural hemoglobin; adjusting a pH value to 5.0 to 8.0; and alternatively vacuumizing and introducing high-purity inert gas for multiple deoxidization. The invention further discloses a preparation process for the natural hemoglobin blood substitute by adopting a deoxygenation technology. According to the deoxygenation method disclosed by the invention, thorough deoxygenation is realized by alternatively vacuumizing and introducing the gas for the multiple times; before deoxygenation, a proper amount of small molecule antioxygen is added for avoiding the phenomenon that the content of MetHb is increased caused by oxygen introduction before and after deoxygenation; compared with a method of deoxdation by only introducing the gas in the subsequent step in the prior art, the method disclosed by the invention has the advantages that deoxygenation is more thorough and quicker; the content of the hemoglobin is less than or equal to 1 percent, or even is as low as 0 percent; and in addition, a proper amount of sugar protectant is added before deoxygenation for sufficiently protecting a natural hemoglobin structure from being damaged in the deoxygenation process, so that activity and curative effect of a final product are ensured.

The present invention relates to methods and sets of drugs for the effective treatment of metastatic cancer and the administration of a set of drugs that overcome mechanisms of resistance to DNA-damaging agents, thereby sensitizing cancer cells to said DNA-damaging agents. The methods involve the administration of a set of drugs comprising melphalan, BCNU, hydroxocobalamin, and ascorbic acid. In a preferred embodiment, ethanol is also added to the set of drugs and bone marrow toxicity is reversed with an infusion of bone marrow stem cells. The methods also involve the depletion of GSH in tumors and the selective delivery of drugs to solid tumors. The methods also involve preventing the loss of catalase function and preventing oxidant-induced hemolysis and / or methemoglobin formation in subjects treated with oxidant drugs or agents that generate hydrogen peroxide, wherein said methods comprise the systemic administration of ethanol.

The invention provides a preparation method of a color chart for rapidly detecting content of methemoglobin. The method comprises the following steps: by respectively taking nitrite solutions with different concentrations as blood samples, drawing an effect-dose relational graph between nitrite and methemoglobin production rate; preparing the blood samples with different methemoglobin concentrations according to the effect-dose relational graph; and respectively dripping the blood samples with different methemoglobin concentrations on a blank color chart for scanning and measuring a red, green and blue (RGB) value, performing statistical analysis, and drawing a color chart of methemoglobin of different concentrations, and finally printing the color chart for use. The color chart prepared by the preparation method can rapidly detect the content of methemoglobin, is simple and convenient to use and is safe and economic.

A device measures blood glucose levels, temperature, heart rate, heart rate variability, respiration, SpO2, blood flow, blood pressure, total hemoglobin (SpHb), PVi, methemoglobin (SpMet), acoustic respiration rate (RRa), carboxyhemoglobin (SpCO), oxygen reserve index (ORi), oxygen content (SpOC) and / or EEG of a human.

An oxygen carrier system includes an artificial oxygen carrier including hemoglobin vesicles encapsulating hemoglobin and an intermediate electron mediator having a standard electrode potential of 0.05 V to 0.56 V (vs. the standard hydrogen electrode) in the vesicles, and a reducing agent which is added to an external aqueous phase of the hemoglobin vesicle to reduce methemoglobin when the hemoglobin encapsulated in the hemoglobin vesicle is oxidized to the methemoglobin. The reducing agent has, as an active component, at least one compound selected from the group consisting of a thiol compound and a reducing sugar.

The invention relates to medicine, in particular to polyhemoglobin-based blood substitutes. The invention can be used for producing blood substituting solutions comparable in terms of a gas transportation efficiency (oxygen transfer) with human blood erythrocytes. The inventive oxygen-transferring blood substitute is based on the hemoglobin which is polymerised by glutaraldehyde produced from animal blood and differs in that it is in the form of a dry substance and contains not less than 90% of polymerised hemoglobin, the molecular mass of which ranges from 192 000 to 320 000 Da and the methemoglobin content in the blood substitute is equal to or less than 5%.

An oxygen carrier system includes an artificial oxygen carrier including hemoglobin vesicles encapsulating hemoglobin and an intermediate electron mediator having a standard electrode potential of 0.05 V to 0.56 V (vs. the standard hydrogen electrode) in the vesicles, and a reducing agent which is added to an external aqueous phase of the hemoglobin vesicle to reduce methemoglobin when the hemoglobin encapsulated in the hemoglobin vesicle is oxidized to the methemoglobin. The reducing agent has, as an active component, at least one compound selected from the group consisting of a thiol compound and a reducing sugar.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The invention relates to a modification method of polymmeric hemoglobin, it is characterized by: preparing purified hemoglobin from natural red blood cells in the condition of 0-4DEG C and nitrogen, first polymerizing them through same type bifunctional reagent, then modifying them with 5'-pyridoxal phosphate. During the modifying process, glutathione should be added after adding PLP 0.5-1.5 hours. The arts can control generation of ferrihemoglobin, but also ensuret the P50 value in appropriate range and reduce production costs greatly.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

A method and an apparatus for regenerating an oxygen-binding ability by reducing the methemoglobin contained in hemoglobin-vesicle by light irradiation. This method includes adding electron donors such as amino acids, saccharides, alcohols, and / or flavin derivatives in appropriate amounts to the inner aqueous phase of the hemoglobin-vesicle, applying light to the vesicle when the content of methemoglobin increases as a result of oxidation of hemoglobin, thereby reducing the metohemoglobin. In this manner, the oxygen-binding ability is recovered, thereby maintaining the function of the hemoglobin-vesicle.

A device measures blood glucose levels, temperature, heart rate, heart rate variability, respiration, SpO2, blood flow, blood pressure, total hemoglobin (SpHb), PVi, methemoglobin (SpMet), acoustic respiration rate (RRa), carboxyhemoglobin (SpCO), oxygen reserve index (ORi), oxygen content (SpOC) and / or EEG of a human

A method for blood haemoglobin measurement without carboxyhaemoglobin interference comprises converting oxyhemoglobin, deoxyhemoglobin and methemoglobin into a methemoglobin derivative, i.e. Imidazole-methemoglobin. Imidazole-methemoglobin and carboxyhemoglobin are collectively quantified by the reflectance spectroscopy of the matrix at 525 nm, the isobestic point between Imidazole-methemoglobin complex and carboxyhemoglobin molecule.

The invention relates to a hemoglobin storage method which is characterized by comprising the following steps of adding a proper quantity of human blood into normal saline (a 0.9% NaCl solution) with the volume being 3-6 times that of the human blood, centrifuging at the temperature of 4 DEG C and the rotating speed of 2800r / min for 15-30 minutes to obtain a supernatant containing leukocytes, plasma proteins and platelets, extruding the supernatant, retaining deposited erythrocytes at the lower layer, repeating the washing process for more than 3-5 times until the supernatant is basically colorless, and removing other substances except for the erythrocytes to the maximum extent to obtain clean deposited erythrocytes; adding a certain quantity of deposited erythrocytes into equivoluminal sterilized high-purity deionized water to pre-expand for 5-15 minutes, finally, adding water with the volume being 2 times that of the deposited erythrocytes to carry out low permeation for 10-20 minutes, centrifuging at the rotating speed of 10000r / min for 30-60 minutes, and extracting the supernatant after centrifuging to obtain a hemoglobin solution; and subpackaging the purified hemoglobin solution into a 10ml sample bottle, sealing by using paraffin, and storing the purified hemoglobin solution in a brown bottle filled with a pyrogallic acid solution at the temperature of 4 DEG C, wherein the content of hemoglobin does not exceed 3% after the sample is stored for 4 months and is kept on the relatively-low level.

Provided is a highly purified and thermostable, cross-linked non-polymeric tetrameric hemoglobin suitable for use in mammals without causing renal damage and vasoconstriction. A high temperature short time (HTST) heat processing step is performed to effectively remove the undesirable dimeric form of hemoglobin, uncrosslinked tetrameric hemoglobin, and plasma protein impurities. Addition of N-acetylcysteine ​​after heat treatment and optionally before heat treatment maintains low levels of methemoglobin. Thermostable cross-linked tetrameric hemoglobin improves and prolongs oxygenation in normoxic and hypoxic tissues. In another aspect, the product is used in the treatment of various types of cancers such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer and esophageal cancer. The tetrameric hemoglobin of the present invention can also be used to prevent tumor metastasis and recurrence after surgical resection of the tumor. In addition the tetrameric hemoglobin of the present invention can be administered to patients prior to chemotherapy and radiation therapy.

The invention relates to blood substitute compositions, and methods of use thereof. Described herein are compositions in which hemoglobin is maintained substantially in the reduced form of hemoglobin as opposed to the oxidized methemoglobin form through inclusion of an oxido-reductase enzyme and reducing agent within a vesicle with the hemoglobin. The vesicles additionally can comprise a dismutase, a catalase, and an electron acceptor, each of which contribute to either the maintenance of hemoglobin in the active oxygen carrying state or provide a benefit not achieved with free hemoglobin.

A method for determining at least one protein in the blood which is more precise while still being simple to implement. The method exploits in an original way the spectroscopy and the dosing techniques to determine accurately the content in proteins of the biological sample, notably for oxyhemoglobin, methemoglobin, heme bound to serum albumin and hemopexin and bilirubin. Such method can advantageously be used in various applications concerning heme-related or hemoprotein-related disorders, notably method for diagnosing, for following a treatment, for determining biomarkers or for screening. Such a method is also interesting for qualifying blood bags.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The present invention aims at providing a method for determining at least one protein in the blood which is more precise while still being simple to implement. The inventors have exploited in an original way the spectroscopy and the dosing techniques to determine accurately the content in proteins of the biological sample, notably for oxyhemoglobin, methemoglobin, heme bound to serum albumin and hemopexin and bilirubin. Such method can advantageously be used in various applications concerning heme-related or hemoprotein-related disorders, notably method for diagnosing, for following a treatment, for determining biomarkers or for screening. Such a method is also interesting for qualifying blood bags.